Difference between revisions of "Imatinib (Gleevec)"
m (→Also Known As) |
|||
| Line 9: | Line 9: | ||
*[http://chemocare.com/bio/imatinib_mesylate.asp Imatinib (Gleevec) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/imatinib_mesylate.asp Imatinib (Gleevec) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/imatinib_mesylate.asp Imatinib (Gleevec) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/imatinib_mesylate.asp Imatinib (Gleevec) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/imatinib-gleevec-patient-drug-information Imatinib (Gleevec) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/imatinib-gleevec-patient-drug-information Imatinib (Gleevec) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/imatinib-gleevec-patient-drug-information Imatinib (Gleevec) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/imatinib-gleevec-patient-drug-information Imatinib (Gleevec) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 5/10/2001: Initial FDA approval | ||
==Also Known As== | ==Also Known As== | ||
Revision as of 15:35, 6 June 2013
General information
Class/mechanism: Tyrosine kinase inhibitor, inhibits multiple tyrosine kinases, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML; the receptor tyrosine kinases for platelet-derived growth factor (PDGF), stem cell factor (SCF), and c-kit, which is the activating mutation found in gastrointestinal stromal tumor (GIST) tumors.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Imatinib (Gleevec) patient drug information (Chemocare)[3]
- Imatinib (Gleevec) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/10/2001: Initial FDA approval
Also Known As
CGP 57148b, Enliven, Gleevac, Imalek, Imatib, Imatinib Mesilate, Imatinib Mesylate, STI-571, Temsan, Veenat.